Norvasc

Mylans EpiPen

Pharma

Pfizer’s bulked-up Viatris may not reap rewards: analysts

Pfizer plans to sell two assets to its Mylan-Upjohn spinoff, adding $598 million in revenues—but that won't do much for its profits, analysts warned.

Arlene Weintraub Jan 29, 2020 12:04pm

Patents on file

Record $179B in lifetime sales leads decade's top patent losses

Aug 17, 2017 8:01am